Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease

F. Colciaghi, E. Marcello, B. Borroni, M. Zimmermann, C. Caltagirone, F. Cattabeni, A. Padovani, Monica Di Luca

Research output: Contribution to journalArticle

Abstract

Amyloid precursor protein (APP), ADAM 10, and β-site-APP cleaving enzyme (BACE) alterations were evaluated in platelets of 31 patients with Alzheimer disease (AD) and 15 age-matched controls. A significant modification of these proteins and enzymes involved in the amyloid cascade was detected from the earliest clinically detectable disease stage. This observation suggests that AD is associated with an early metabolic derangement toward amyloidogenic pathways and supports the potential value of APP and secretase measurements for early diagnosis of AD.

Original languageEnglish
Pages (from-to)498-501
Number of pages4
JournalNeurology
Volume62
Issue number3
Publication statusPublished - Feb 10 2004

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease'. Together they form a unique fingerprint.

  • Cite this

    Colciaghi, F., Marcello, E., Borroni, B., Zimmermann, M., Caltagirone, C., Cattabeni, F., Padovani, A., & Di Luca, M. (2004). Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology, 62(3), 498-501.